Ocera Therapeutics (OCRX) Reports Q4 Loss of $0.22/Share

Ocera Therapeutics (NASDAQ: OCRX) reported Q4 EPS of ($0.22), versus ($0.34) reported last year.

Financial Guidance

Ocera anticipates it will have sufficient cash to fund operations into the second quarter of 2018 based on its current operating plan and re-prioritization of certain development activities

For earnings history and earnings-related data on Ocera Therapeutics (OCRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c